AbCellera Biologics Inc. announced its financial results for the first quarter of 2025, reporting total revenue of $4.2 million. The company experienced a net loss of $45.6 million, compared to a net loss of $40.6 million in the same period of 2024. Sales and marketing expenses decreased to $2.8 million from $3.4 million in Q1 2024, while general and administrative expenses were reduced to $16.2 million from $17.4 million in the previous year. The company reported having $633 million in total cash, cash equivalents, and marketable securities, with approximately $178 million in available non-dilutive government funding, culminating in a total available liquidity of around $810 million. Significantly, AbCellera highlighted the introduction of ABCL635, a potential first-in-class antibody targeting non-hormonal treatment of vasomotor symptoms associated with menopause. The company also announced reaching a cumulative total of 97 partner-initiated program starts with downstreams and 16 molecules having reached the clinic by the end of the quarter.